Pasadena, California, August 1, 2021
Promis Diagnostics, Inc., announced that it will be relocating to a new facility in Irvine later this year. The new facility will provide adequate laboratory space for their increased number of projects. Promis Dx is planning to launch their clinical trials for multiple cancer diagnostic projects as soon as the move is complete.
About Promis Diagnostics
Promis Dx has developed and commercialized DNA methylation biomarker-based non-invasive cancer molecular diagnostic products for early detection of cancer (colorectal, lung, bladder cancer, etc.), and is in the process of developing products for companion diagnostics of cancer and various infectious diseases. Based in Pasadena, California, Promis Dx is CAP accredited, CLIA certified, and CDPH licensed laboratory. www.promisdx.com